Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LTB-NG6 Vaccine Against Neisseria Gonorrhoeae
NCT07758972Phase 1Recruiting
- Sponsor
- LimmaTech Biologics
- Start
- Aug 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 1, randomised trial of LTB-NG6 in gonorrhea (6 arms), sponsored by LimmaTech Biologics. Primary endpoints: Adverse Events at 18 months and Immunoglobulin G Geometric Mean Titer. Started Aug 2026; status: recruiting.
02
Drugs
LTB-NG6
03
Conditions
gonorrhea
Beyond the preview
Go deeper on NCT07758972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07758972.